Proxima Joins Truthset Data Collective, Validating Best‑in‑Class Data Quality
NEW YORK--(BUSINESS WIRE)-- Proxima, a data intelligence software company that helps marketing teams scale customer acquisition profitably, today announced it has joined the Truthset Data Collective, a group of leading businesses empowering the marketing industry to act on data with the highest degree of quality. By joining the Data Collective, Proxima reinforces its commitment to data accuracy, reliability, and security.
Validated. Verified. Vetted. Proxima's data platform is now Truthset-approved and meets the industry's highest standard for accuracy, quality, and reliability.
Share
Truthset, the leading data validation company, formed the Data Collective to provide an agnostic, independent platform for businesses to share and benchmark the accuracy of their marketing data. As data-driven marketing has become crucial for brands to reach consumers, the Data Collective is a multi-sourced arbiter to standardize data accuracy for audience targeting and media measurement.
Launched in 2022, Proxima is building an AI-powered marketing platform trained on the world's largest DTC commerce graph. Their predictive models analyze over $20B in eCommerce transactions and 64 million anonymized shopper profiles to help marketers reach and convert high-value customers across their advertising ecosystem with unparalleled efficiency.
As a newly minted member of the Truthset Data Collective, Proxima has received the highest caliber of data validation, ensuring its unique dataset meets the industry-leading standards of quality and accuracy.
"Brands and agencies are increasingly prioritizing retail and transaction data across their marketing channels to drive better outcomes," said Alex Song, CEO of Proxima. 'Proxima has unlocked a significant and highly valuable area of DTC commerce through our unique data intelligence, empowering marketers to achieve new heights of performance. Joining the Truthset Data Collective is essential to our vision as it reinforces our commitment to providing high-quality, trustworthy data intelligence that drives better results for our partners and the industry."
'Proxima's approach to DTC commerce delivers a unique set of data intelligence solutions to the market,' said Scott McKinley, CEO of Truthset. 'We're excited to welcome them to the Data Collective and look forward to collaborating to raise the bar for data accuracy across the marketing industry.'
This partnership reinforces Proxima's commitment to data quality, giving its partners confidence that its consumer datasets are reliable, accurate, and effective in supporting the precision and profitability of their data-driven marketing strategies.
Proxima's induction into the Data Collective follows the recent launch of their DTC segments for programmatic advertising, now available in the data marketplaces of popular DSPs including The Trade Desk and Yahoo. Programmatic advertisers and agency traders can now seamlessly activate digital ad campaigns against Proxima's high-value, unmodeled, 100% deterministic DTC consumer segments within their preferred DSP.
About Proxima
Proxima is transforming the consumer technology landscape and giving B2C businesses the data they need to make informed decisions that drive superior marketing performance. Proxima is a first-of-its-kind data intelligence solution that securely leverages artificial intelligence and a proprietary data network to enable businesses to achieve greater scale, efficiency, and financial success across their marketing stack. Their mission is to be the essential intelligence platform for powering marketing performance for all consumer businesses. Learn more about Proxima here.
About Truthset
Truthset is the leading consumer data validation company. The company helps brands build trust in data, and improve the performance of any data-driven decision. Truthset does not sell data and is not a data broker; it compiles a likelihood of truth for any individual record that can be used to validate the accuracy of data and power more accurate consumer interactions. Truthset was founded in 2019 by industry veterans from Nielsen, Salesforce, LiveRamp, and Procter & Gamble. Truthset is funded by venture investors. The company is headquartered in San Francisco. Learn more about Truthset here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 hours ago
- Yahoo
Ensueño Laundry is Bringing The Abuela Attitude Right To Your Laundry Room with the "Abuela Tag Reader" Campaign
The Mobile Activation Will Offer Abuela-Approved Laundry Advice To Help Decipher Any Laundry Tag HOUSTON, June 11, 2025 /PRNewswire/ -- Ensueño Laundry, the premier complete portfolio laundry care brand and a favorite among Hispanic-American households, has created a new digital experience, "Abuela Tag Reader" to help translate laundry care tags into simple directions to get the best clean possible. Oftentimes, the symbols on a laundry care tag can seem like hieroglyphics. It can feel like you're trying to crack a secret code, and if you're wrong you could end up with your favorite shirt coming out of the dryer looking like it's made for a baby doll. With the Abuela Tag Reader, real-life abuelas will guide users through what each symbol means, washing best practices, drying techniques, and more. That means some tough love, a little bit of sass, and a lot of lessons learned all on-demand when you need it. "In Latino culture, there's an Abuela way to do your laundry and a wrong way to do your laundry," said Cristina Mustieles, Senior Brand Manager, at Ensueño. "These matriarchs have decades of experience, so what better way to share 'expert advice' than by having it come from the true, original source? There's a sense of love there; they want you to succeed. But, there's also some spice; they will call you out if you do it wrong or don't listen. This is such a fun campaign because it really strikes that balance between being a helpful resource and the nostalgia of your own grandmother scoffing as if she were the one teaching you." Laundry can often feel like a burdensome chore, but the Abuela Tag Reader aims to add a fun and engaging twist to learning about laundry. The digital mobile-first experience makes it easy to utilize in day-to-day life whether you're a laundry veteran who is stumped on how to approach a delicate fabric or doing your first load on your own and encounter a symbol you've never seen before. The abuelas' breakdown instructions are simple – and even a little cheeky. Customers can visit on their mobile device to scan any laundry care tag. The webpage will act as a hub of information, containing videos from abuelas that break down how to tackle even the most confusing of laundry care tags. In addition, customers will be able to redeem a coupon for $2 off select Ensueño products at H-E-B while supplies last. The abuela is an icon in Hispanic culture – she is the heart and soul of the family. She's a source of wisdom, love and comfort but with a presence deserving of respect. The Abuela Tag Reader experience aims to bottle that familiar feeling, sharing a small piece of Ensueño's heritage with people from all cultures. Beautifully blunt and always there when you need it, the Abuela Tag Reader makes deciphering laundry easy, silly, and entertaining. For more information on the campaign and to try out the Abuela Tag Reader yourself, please visit About AlEn USA Headquartered in Houston, Texas, AlEn USA is a subsidiary of Grupo AlEn, a cleaning and laundry products company with a presence in Mexico, Central America, and the Caribbean. With more than 5,000 employees globally, Grupo AlEn has been striving for a cleaner and more sustainable world for 75 years. In the U.S., AlEn's portfolio of products includes bleach, cleaners, and laundry products, under the brands CLORALEN®, PINALEN®, and ENSUEÑO®. One of the few consumer goods products companies based in Houston, AlEn USA is committed to continued growth and innovation of its products in the U.S., supporting a culturally diverse workforce and maintaining socially responsible and sustainable business practices. For more information, visit View original content: SOURCE AlEn USA
Indianapolis Star
12 hours ago
- Indianapolis Star
First Study Site Established for Jaguar Health Study of its FDA Conditionally Approved Canalevia-CA1 Prescription Drug for Dogs
Two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) and to expand the indication of crofelemer from CID to treatment of general, non-infectious diarrhea in dogs Jaguar in discussions with potential partners to license and fund development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S. and/or globally Diarrhea is one of the most common reasons for veterinary visits for dogs and the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs SAN FRANCISCO, CA / ACCESS Newswire / June 11, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), under its Jaguar Animal Health tradename for the veterinary market, today announced that the first study site has been established for Jaguar's field study of Canalevia-CA1, Jaguar's U.S. Food and Drug Administration (FDA) conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Jaguar has two parallel goals for Canalevia-CA1 (crofelemer delayed-release tablets): To obtain full approval of the drug for treatment of chemotherapy-induced diarrhea (CID) in dogs and to expand the indication of crofelemer from CID in dogs to treatment of general, non-infectious diarrhea in dogs. The company is in discussions with potential partners to fund development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S. and/or globally. 'We've been pleased with the marketplace reception of crofelemer for treatment of CID in dogs, and believe there is clearly an unmet medical need for a product for the much larger market of treatment of general, non-infectious diarrhea in dogs,' said Lisa Conte, Jaguar's Founder and CEO. 'We estimate that U.S. veterinarians see approximately six million annual cases of acute and chronic diarrhea in dogs, and we look forward to identifying a partner to fund and execute development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in the U.S and/or globally. Forging a partnership for this purpose is a key focus of our business development efforts in 2025 and has been designated as a key potential catalyst for the company this year.' 'Jaguar's canine-focused business development efforts align with our ongoing business development efforts on the 'human' side of the company for crofelemer – the catalysts for which are the pathways discussed with the FDA to bring crofelemer to metastatic breast cancer patients, a population we feel meets the requirements for orphan drug status; and the prompt establishment of an expanded access program for crofelemer for the ongoing important unmet medical need of cancer therapy-related diarrhea in breast cancer patients; and the initial proof-of-concept results from the ongoing investigator-initiated trial (IIT) of a novel liquid formulation of crofelemer in Abu Dhabi in pediatric patients with intestinal failure due to the orphan diseases microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF). As recently announced, the initial proof-of-concept results of this IIT show crofelemer reduced the required total parenteral nutrition (TPN) and/or supplementary intravenous fluids, collectively referred to as parenteral support, in patients with intestinal failure due to MVID and short bowel syndrome by up to 27% and 12.5% respectively.' The objective of the prospective, randomized, open-label field study in dogs undergoing chemotherapy treatment across the U.S. is to collect real-world data to demonstrate real-world evidence of the clinical effectiveness for Canalevia-CA1 for the treatment of CID in dogs to support potential full FDA approval of the drug for this indication. Dogs enrolled in this study will be randomly assigned to receive a prescription of Canalevia-CA1 as a treatment for CID or be randomly selected to the control group. As announced, Jaguar established a new Investigational New Animal Drug (INAD) file with the FDA's Center for Veterinary Medicine for crofelemer to treat general, non-infectious diarrhea in dogs. Diarrhea is one of the most common reasons for veterinary office visits for dogs and is the second most common reason for visits to the veterinary emergency room, yet there are currently no FDA-approved drug to treat canine general, non-infectious diarrhea. According to the American Veterinary Medical Association, there were an estimated 89.7 million dogs in the United States in 2024, with nearly half (45.5%) of U.S. households owning a dog in 2024. Devastating diarrhea-related dehydration can occur rapidly for the animal, and the lack of control in urban settings where owners don't have easy access to outdoor facilities is a significant problem for families with dogs. Canalevia-CA1, a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, is available from multiple leading veterinary distributors in the U.S., including Chewy. About Conditional Approval and Full Approval Canalevia-CA1 initially received conditional approval in December 2021 from the FDA for the treatment of CID in dogs. FDA's conditional approval allows a drug company to legally promote, advertise and sell the animal drug for the labeled uses before proving it meets the 'substantial evidence' standard of effectiveness for full approval. The conditional approval is valid for one year. The drug company can ask the FDA to renew the conditional approval annually for up to four more years, for a total of five years of conditional approval. To receive a renewal from the FDA, the company must show active progress toward proving 'substantial evidence of effectiveness' for full approval. After collecting the remaining effectiveness data, the company then applies to the FDA for full approval. The FDA reviews the application and, if appropriate, fully approves the drug. About Chemotherapy-induced Diarrhea (CID) in Dogs According to the American Veterinary Medical Association, approximately 1 in 4 dogs will, at some stage in their life, develop cancer, and almost 50% of dogs over age 10 will develop cancer. 1 According to the National Cancer Institute, which is part of the National Institutes of Health, roughly 6 million new cancer diagnoses are made in dogs each year in the U.S. Due to the increasing number of chemotherapeutic agents being adopted by veterinary oncologists and primary care veterinarians, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment, 2 and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the U.S. veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients' chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID. Canalevia-CA1 is a tablet that can be given orally twice a day and can be used for home treatment of CID in dogs. About Canalevia ® -CA1 Canalevia-CA1 (crofelemer delayed-release tablets) is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval. Jaguar has also received Minor Use in a Major Species (MUMS) designation from the FDA for Canalevia-CA1 to treat CID in dogs. FDA has established a 'small number' threshold for minor use in each of the seven major species covered by the MUMS act. The small number threshold is currently 80,000 for dogs, representing the largest number of dogs that can be affected by a disease or condition over the course of a year and still have the use qualify as a minor use. About Crofelemer Crofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program, under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities. Important Safety Information About Canalevia ® -CA1 For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting. Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552. About the Jaguar Health Family of Companies Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications. For more information about: Jaguar Health, visit Napo Pharmaceuticals, visit Napo Therapeutics, visit Magdalena Biosciences, visit Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram Forward-Looking Statements Certain statements in this press release constitute 'forward-looking statements.' These include statements regarding Jaguar's expectation that it will identify a partner to fund and execute development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S and/or globally, Jaguar's expectation that the U.S. population of metastatic breast cancer patients meets the requirements for orphan drug status, Jaguar's expectation that it will promptly establish an expanded access program for crofelemer for cancer therapy-related diarrhea in breast cancer patients, and Jaguar's expectation that the field study of Canalevia-CA1 for the treatment of CID in dogs will support potential full FDA approval of the drug for this indication. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. 1 'Cancer in Pets.' American Veterinary Medical Association, 2021, 2 Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398 Contact: hello@ Jaguar-JAGX SOURCE: Jaguar Health, Inc.
Yahoo
15 hours ago
- Yahoo
Herbalife's Aloin Identification Method for Aloe Vera Officially Recognized by AOAC INTERNATIONAL
Certified Method Enhances Global Botanical Quality and Safety LOS ANGELES, June 11, 2025--(BUSINESS WIRE)--Herbalife Ltd. (NYSE: HLF), a premier health and wellness company, community and platform, today announced the Association of Official Analytical Collaboration (AOAC INTERNATIONAL)—a global authority in analytical science—has formally certified its proprietary method for identifying and measuring anthraquinones, also known as aloins, in aloe vera. Aloe regulatory groups require producers of ingestible aloe vera products to monitor naturally occurring compounds such as aloin A, aloin B, and aloe-emodin to meet safety guidelines. This certification officially recognizes Herbalife's longstanding method as the world's first AOAC-approved approach for detecting aloins—reinforcing safety and quality benchmarks across botanical and dietary supplement industries. Developed by Herbalife scientists and validated by independent laboratories worldwide, this AOAC-certified method is used to test every batch of Herbalife's aloe-based products, ensuring safety, while preserving aloe vera's natural benefits. Aloe vera is a key ingredient in many of Herbalife's top products, which are sold in more than 90 markets. "This AOAC validation is an important milestone for Herbalife and the industry as a whole," said Gary Swanson, SVP of Global Quality at Herbalife and lead author of the study. "We are proud to lead scientific innovation that enhances botanical ingredient safety, benefitting not only Herbalife products and our customers, but also advancing standards across the industry." Herbalife's method was validated through a global multi-laboratory study involving eight independent laboratories. Each lab tested the same set of six aloe vera samples, including both raw materials and finished products, using HPLC (High-Performance Liquid Chromatography) to measure aloin A, aloin B, and aloe-emodin. The study ensured the method's accuracy and reliability across various labs and product types, with results confirming that it met all performance criteria, including precision and system suitability. "This multi-laboratory validation study supported approval of an analytical method developed by Herbalife scientists as the AOAC 2016.09 Official Final Action Method," said Dr. Katerina Mastovska, deputy executive director and chief science officer, AOAC INTERNATIONAL. "AOAC official methods undergo rigorous scientific evaluation and are highly credible and globally accepted. As such, this method will help strengthen botanical quality and safety standards worldwide." Herbalife has a long-standing commitment to aloe vera research and quality assurance. This dedication has resulted in five patents and three published studies focused on developing safe extraction methods that preserve the plant's natural benefits. While many companies rely solely on supplier certifications to confirm the authenticity of their aloe vera, Herbalife goes further. The company is one of the few in the world using advanced proton nuclear magnetic resonance (NMR) spectrometry—an analytical technique that uses magnetic fields and radio waves to identify the molecular structure of raw materials. This allows Herbalife to independently verify the identity and purity of its aloe vera at the molecular level, ensuring the highest standards of quality, consistency and traceability across its global supply chain. For 45 years, Herbalife has upheld a global commitment to quality through its rigorous Seed to Feed process. This comprehensive system ensures that every ingredient—from responsibly sourced crops cultivated by dedicated farmers to the finished product—meets stringent standards for identity, potency, safety, and purity. Herbalife performs internal testing in ISO 17025-accredited laboratories, verifying that ingredients comply with both company standards and government regulations. The company's science-backed approach, grounded in Good Manufacturing Practices (GMPs) and NSF International standards, delivers consistent, transparent products in more than 90 markets. Supported by a global team of scientists and quality experts, this process strengthens consumer trust and continues to advance industry standards worldwide. Herbalife's aloe vera testing method has been published in Journal of AOAC INTERNATIONAL (Volume 108, Issue 3, Pages 449-471). About Herbalife Ltd. Herbalife (NYSE: HLF) is a premier health and wellness company, community and platform that has been changing people's lives with great nutrition products and a business opportunity for its independent distributors since 1980. The Company offers science-backed products to consumers in more than 90 markets through entrepreneurial distributors who provide one-on-one coaching and a supportive community that inspires their customers to embrace a healthier, more active lifestyle to live their best life. For more information, visit View source version on Contacts Media Contact: media@
